MIM
IBIO icon

Monashee Investment Management’s iBio IBIO Stock Holding History

Monashee Investment Management’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-274,862
Closed -$530K – 50
2025
Q4 		$530K Buy
+274,862
New +$375K 0.3% 40

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Monashee Investment Management's IBIO Position: Q1 2026 in Review

Monashee Investment Management sold out of iBio (IBIO) in Q1 2026, closing a stake of 274,862 shares — an estimated $530K sold.

Monashee Investment Management first reported a position in IBIO in Q4 2025 and held it in 1 quarter. The position peaked at $530K in Q4 2025. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

  • Monashee Investment Management reported no remaining iBio position as of Q1 2026 after selling out during the quarter.
  • Monashee Investment Management sold 274,862 iBio shares in Q1 2026, an estimated $530K.
  • Monashee Investment Management first reported a position in iBio in Q4 2025 and held it in 1 quarter.
  • Monashee Investment Management's iBio position peaked at $530K in Q4 2025.
  • 52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on Monashee Investment Management's 13F filing for Q1 2026, filed 13 May 2026.